Sandbox Reserved 1790
From Proteopedia
SHOC2-PP1C-MRASIntroduction(SMP) is a ternary holophosphotase complex formed by the individual proteins: SHOC2, PP1C, and MRAS. The SMP complex is involved in signaling the initiation of MAPK pathways, which is responsible for cellular growth and development, cell proliferation, and apoptosis [1]. Formation of this complex begins with an extracellular signal binding to a membrane-embedded receptor tyrosine kinase(RTK) [1]. This causes membrane-bound MRAS to exchange GDP for GTP. Initiating the SMP complex formation at the plasma membrane consists of the SHOC2 and PP1C binding first. When the MRAS exchanges GDP to GTP, it then assembles with the combined SHOC2 and PP1C. Based on MRAS targeting, PP1C catalyzes the dephosphorylation of the N-terminal phosphoserine (NTpS) on the RAF complex leading to the amplification of MAPK signaling [1]. In a normal cell, this would regulate cell proliferation but dysfunction in the ternary complex has shown signs to lead to tumor formation due to unregulated cell growth [1]. Overall StructureSHOC2is a scaffold protein composed of 20 leucine-rich repeat (LRR) domains that form a solenoid structure [1]. The leucine-rich region forms a concave hydrophobic core which is necessary for binding with PP1C and MRAS. SHOC2 is the crucial mediator for SHOC2-PP1C-MRAS complex formation [1]. The leucine-rich domain is very important in creating selectivity for the PP1C protein, as that protein is used for so many other complex pathways [1]. The LRR domains are stabilized by an N-terminal flanking 𝝰-helix and a C-terminal helix-turn-helix [2]. Alongside the conserved leucine residues in the LRR domain, there is a group of conserved asparagine residues that creates a stabilizing “asparagine ladder” that is necessary for the LRR fold, giving the SHOC2 its concave structure [2]. SHOC2 is also capable of causing various forms of cancers and rasopathies. A common one is caused by a mutation known as p.S2G [3]. This mutation causes the formation of an additional 14-carbon saturated fatty acid chain on the N-terminal glycine of SHOC2 [3]. This causes SHOC2 to become attached to the cell membrane, resulting in prolonged dephosphorylation of RAF by PP1C [3]. With this abnormality, there is overexpression of the MAPK pathway and increased cell proliferation genes [3]. This can cause the formation of various tumors in the body. Other mutations of the SMP ternary structure as a whole can also lead to the development of Noonan syndrome [1]. PP1Cis a phosphatase. After forming a ternary complex, the hydrophobic active site on PP1C interacts with RAF and dephosphorylate Ser 259. PP1C's active site is adjacent to a hydrophobic binding pocket that binds to the C-terminal phosphoserine, located on the N-terminus of RAF, the target for dephosphorylation. PP1C can act as a phosphatase in the absence of SHOC2 but PP1C lacks intrinsic substrate selectively. The SMP complex formation endows PP1C with specificity for RAF [1]. The mechanism that PP1C uses to catalyze the dephosphorylation is mainly through donating a hydrogen atom to a phosphate group on the C-terminal of a phosphoserine on RAF [4]. This makes the phosphate group a good leaving group and it breaks off [4]. This catalysis is done by the serine-threonine alpha catalytic site on PP1C [4]. In this catalytic site, there are two Manganese ions and one calcium ion [4]. These metal ions are necessary for stabilizing this catalytic site and there are a lot of polar negative residues in this region [4]. The catalytic site is also capable of causing various rasopathies if there is a mutation present [3]. Typically the mutation is centered around the catalytic site not being able to attach to the dephosphorylation site on Ras [3]. This causes an underproduction of cell proliferation pathways and leads to Rasopathies. RASopathy is a broad term used to describe developmental syndromes that stem from germline mutations of proteins along the RAS/MAPK pathway. These mutations can be either gain or loss of function. Rasopathies can also lead to cancer [3]. The mutation in PP1C can result in damage to growth and development in multiple areas of the body .[3] SHOC2 and PP1C interactionson its leucine rich region(LRR). Between LRR2 and LRR5 and between LRR7 and LRR11. Mutations between SHOC2 and PP1C to the LRR were shown to completely inhibit the binding of PP1C. Five main are made between PP1C and SHOC2 respectively: E56-R182, E167-R203, E54-K180, R187-H178, R188-E155 [2]. Reflecting this ionic character, the binding regions are contained within extensive acidic and basic patches on and . The negative acidic patches of PP1C interact with the positive basic patches of SHOC2 and vice versa to form a . These interactions do not result in significant conformational changes to PP1C in comparison to other protein interactions that can be made with PP1C [2]. MRASis a monomeric GTPase. MRAS is membrane-bound due to post-translational lipidation, which results in lipidated residues located near the C-terminus. This lipidation allows the protein to interact with the inner membrane leaflet [5][6]. MRAS localizes the SMP complex near RAF and other components of downstream signaling. The region of MRAS not directly bound to the membrane binds SHOC2 and PP1C to orient the complex such that PP1C’s active site faces the serine that will get dephosphorylated on RAF. MRAS also controls SMP complex formation in connection with extracellular signaling based on its dualistic switching between its inactive and active state. In its inactive state, MRAS is bound to GDP. When signaled by growth factors, the GDP is exchanged for GTP when a ligand binds to the RTK [1]. The now undergoes a conformational change of the . These regions are the major binding sites with SHOC2. This conformational change activates MRAS allowing it to bind with the SHOC2-PP1C complex. In its inactive GDP-bound state, MRAS is sterically occluded from binding SHOC2. For example, R83 of GDP-bound MRAS directly clashes with SHOC2 as shown in Figure 1. In comparison to other RAS proteins such as H/K/NRAS, MRAS has a greater affinity for the SHOC2-PP1C complex[4]. This indicates that the specific structure of MRAS is necessary for SMP function. While MRAS engages the SHOC2-PP1C complex to bring the complex to the membrane, an additional membrane-bound RAS binds RAF nearby. This binding is also stimulated by ligand binding to the RTK. This indicates that for full RAF activation and continuous signaling of RAF, two separate active RAS proteins are needed. Having two MRASs also help with the co-localization of PP1C to the NTpS region on RAF. To inactivate RAF signaling, MRAS uses its intrinsic GTPase to remove the activating gamma-phosphate on GTP. In the GDP-bound state, switch I and II move to the position shown in green in Figure 1. This inactivates SHOC2 binding due to steric clashing which causes the SMP structure to dissociate. SHOC2 and MRAS interactions MRAS is initially bound to GDP causing it to be in its inactive state. Inactive GDP-MRAS cannot bind to the SHOC2-PP1C complex due to steric clashing of the switch I and II regions of MRAS and its binding zone on SHOC2. Once GDP is exchanged for GTP when signaled by growth factors, MRAS is activated and conformational changes occur within the switch I and switch II regions to allow . These between SHOC2 and the switch I and II regions of MRAS include hydrogen bonds, ionic interactions, and π stacking. There is a hydrogen bond at R288-Q71 and ionic interaction at R177-E47. π staking occurs at R104-R83. These interactions occur between SHOC2 and MRAS respectively [7].
PP1C and MRAS The interactions between are respectively mediated by four main : ionic interactions are between D48-R188 and H53-D197, hydrogen bonds are between K36-Q198 and Q35-M190. As the complex forms, the active site for the dephosphorylation of RAF's S259 is oriented such that it remains accessible for RAF [1]. The relative order of complex ordering is still an area of debate. Some experiments indicate that PP1C must bind to SHOC2 before MRAS binds[7] but others indicated that PP1C and MRAS can bind to SHOC2 at the same time [1]. Signaling PathwayThe SMP signaling pathway begins with the formation of the SMP complex. Initially, a ligand must bind to a receptor tyrosine kinase. This signals SHOC2 to bind to PP1C forming a binary complex that then binds to the membrane-bound MRAS. There is some discrepancy about when the different proteins of the SMP complex come together [8], however, we chose to depict the order as shown in Figure 3 for more clear visualization. Some experiments indicate that the three proteins bind at the same time but the order is largely unknown. Once the SMP complex forms, its intracellular target is a key inactivation phosphorylation (Ser259) on MAPK RAF-1. The serine is directly dephosphorylated by PP1C, while SHOC2 and MRAS increase PP1C’s specificity for S259 on RAF [8]. When analyzing the surface structure of SHOC1-PP1C-MRAS, there was a hydrophobic groove on the SHOC2 terminus and another hydrophobic groove near the active site on PP1C [8]. This region is crucial in making PP1C specific to RAF because the NTpS region that is right next to the phosphoserine on RAF is able to bind to the hydrophobic patch on both SHOC2 and PP1C [8]. Mutations affecting SMP complex formation and stability can increase or decrease MAPK signaling, where increased stability of the complex increases MAPK signaling, decreased stability decreases signaling [8]. There are a set of mutations that can happen on the SMP complex as a whole that can cause Noonan syndrome, a rasopathy disorder [1]. On SHOC2, the following mutations S2G, C260Y, and P510L caused differences in the complex formation with PP1C. On PP1C, the mutation P50R resulted in stronger ionic interactions with residues on SHOC2, causing a more stabilized complex. On MRAS, mutations G23V and T681I, increased the proportion of MRAS that is GTP bound, which results in increased affinity in the SMP complex overall [8]. If these mutations happen all at once, or just one or two at a time, it can still significantly alter the functionality of the SMP complex. This can lead to diseases like Noonan syndrome, which is where there are developmental and growth issues and can even lead to cancers [3]. Future StudiesWith this understood knowledge about how the SMP is able to contribute to an increase or decrease of MAPK pathways, there can be further research done to develop treatments for various cancers and rasopathies [8]. Research can be done to develop inhibitors that can alter the affinity of the SMP complex in order to regulate MAPK signaling pathways. This can help treat diseases that are caused by unregulated cell proliferation[7]. Another possible point of inhibition is the growth factor that signals SHOC2-PP1C and Raf to the cell membrane [8].  References
Student ContributorsMadeline Gilbert Inaya Patel Rushda Hussein | ||||||||||||
